Christopher has more than 20 years’ experience in early-stage pharmaceutical R&D and commercialisation in companies financed by both public and private equity.
He was Research Director and a technology founder at ASX-listed Antisense Therapeutics Ltd, an Ionis Pharmaceuticals satellite company. Christopher has guided RNA-targeting drugs from research through to the clinic and commercial exit.
As CEO, he navigated a small molecule nasal spray product from concept through Phase 1b and exit in 5 years at Otifex, and he built a company structure and team that made the most advanced direct Myc inhibitor for cancer at MycRx.
Christopher has a PhD in Biochemistry and an MBA specialising in Technology Management. He was a Guest Scientist and Humboldt Fellow at the German Cancer Research Centre in Heidelberg, and in 2008 he received the Advance BioBusiness Award for leadership in the Australian Life Sciences sector.